IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma

被引：0

作者：

Miller, M. ^{[1
]}

Sahin, U. ^{[2
]}

Derhovanessian, E. ^{[3
]}

Kloke, B-P. ^{[1
]}

Simon, P. ^{[4
]}

Bukur, V. ^{[5
]}

Albrecht, C. ^{[6
]}

Paruzynski, A. ^{[5
]}

Loewer, M. ^{[7
]}

Kuhn, A. ^{[8
]}

Schreeb, K. ^{[9
]}

Attig, S. ^{[10
]}

Brueck, A. Kemmer ^{[9
]}

Bolte, S. ^{[9
]}

Grabbe, S. ^{[11
]}

Hoeller, C. ^{[12
]}

Utikal, J. ^{[13
]}

Huber, C. ^{[14
]}

Loquai, C. ^{[11
]}

Tuereci, O. ^{[15
]}

机构：

[1] Biopharmaceut New Technol BioNTech Corp, Project Management, Mainz, Germany

[2] Biopharmaceut New Technol BioNTech Corp, Management, Mainz, Germany

[3] Biopharmaceut New Technol BioNTech Corp, Immunomonitoring, Mainz, Germany

[4] Biopharmaceut New Technol BioNTech Corp, Immunoreceptor Validat, Mainz, Germany

[5] Biopharmaceut New Technol BioNTech Corp, Genom, Mainz, Germany

[6] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Genom, Mainz, Germany

[7] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Bioinformat, Mainz, Germany

[8] Biopharmaceut New Technol BioNTech Corp, RNA Biochem, Mainz, Germany

[9] Biopharmaceut New Technol BioNTech Corp, Clin Res, Mainz, Germany

[10] Johannes Gutenberg Univ gGmbH, Univ Med Ctr, TRON Translat Oncol, Immunmonitoring, Mainz, Germany

[11] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dermatol, Mainz, Germany

[12] Med Univ Vienna, Dermatol, Vienna, Austria

[13] German Canc Res Ctr, Dermatol, Heidelberg, Germany

[14] Biopharmaceut New Technol BioNTech Corp, Advisory Board, Mainz, Germany

[15] CI3 Cluster Individualized Immunointervent, Management, Mainz, Germany

来源：

ANNALS OF ONCOLOGY | 2017年 / 28卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2

共 50 条

[1] IVAC® MUTANOME - A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
Miller, Matthias
Loquai, Carmen
Kloke, Bjorn-Philipp
Attig, Sebastian
Bidmon, Nicole
Bolte, Stefanie
Bukur, Valesca
Derhovanessian, Evelyne
Diekmann, Jan
Filbry, Angela
Heesch, Sandra
Hoeller, Christoph
Kuehlcke, Klaus
Langer, David
Loewer, Martin
Mueller, Felicitas
Ortseifer, Inga
Otte, Burkhard
Paruzynski, Anna
Rae, Richard
Schroers, Barbara
Seck, Christine
Spiess, Kristina
Tadmor, Arbel D.
Vogler, Isabel
Vormehr, Mathias
Kemmer-Brueck, Alexandra
Kuhn, Andreas N.
Luxemburger, Ulrich
Kreiter, Sebastian
Utikal, Jochen
Grabbe, Stephan
Tuereci, Oezlem
Sahin, Ugur
CANCER RESEARCH, 2016, 76
[2] A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent melanoma immunotherapy
Jabulowsky, Robert A.
Loquai, Carmen
Utikal, Jochen
Hassel, Jessica
Kaufmann, Roland
Derhovanessian, Evelyna
Diken, Mustafa
Kranz, Lena M.
Haas, Heinrich
Attig, Sebastian
Anft, Christine
Buck, Janina
Diekmann, Jan
Fritz, Daniel
Hartmann, Kerstin
Kemmer-Brueck, Alexandra
Kuehlcke, Klaus
Kuhn, Andreas N.
Langguth, Peter
Luxemburger, Ulrich
Meng, Martin
Rae, Richard
Sari, Fatih
Schwarck-Kokarakis, Doreen
Stein, Malte
Grabbe, Stephan
Kreiter, Sebastian
Tuereci, Oezlem
Huber, Christoph
Sahin, Ugur
CANCER RESEARCH, 2017, 77
[3] FIRST-IN-HUMAN PHASE I/II CLINICAL TRIAL OF IG-TREGS FOR GVHD PREVENTION
Lysandrou, Memnon
Kefala, Dionysia
Christofi, Panagiota
Liga, Maria
Miggos, Antonis
Papagregoriou, Charys
Vlachonikola, Elisavet
Savvopoulos, Nikolaos
Zacharioudaki, Vassiliki
Vallianou, Ioanna
Sagiadinou, Eleutheria
Tsokanas, Dimitris
Theodorellou, Rodanthy
Papadopoulou, Anastasia
Triantafyllou, Evi
Sakellari, Ioanna
Costeas, Paul
Chatzidimitriou, Anastasia
Yannaki, Evangelia
Spyridonidis, Alexandros
BONE MARROW TRANSPLANTATION, 2024, 59 : 534 - 535
[4] VLP peanut first-in-human Phase I clinical trial: Patient centred selection approach
Starchenka, Sviatlana
Zuiani, Chiara
Wilkie, David
Eser, Sema
Meneghesso, Silvia
Adura, Peter
McArdle, Eamonn
Schroeder, John
Hamilton, Robert
Skinner, Murray
Kramer, Matthias
Cadavez, Lisa
Shamji, Mohamed
Layhadi, Janice
De Kam, Pieter-Jan
CLINICAL AND EXPERIMENTAL ALLERGY, 2024, 54 (10): : 844 - 845
[5] FIRST-IN-HUMAN PHASE I/II CLINICAL TRIAL OF IG-TREGS FOR GVHD PREVENTION
Lysandrou, M.
Kefala, D.
Christofi, P.
Liga, M.
Miggos, A.
Papagregoriou, C.
Vlachonikola, E.
Savvopoulos, N.
Zacharioudaki, V.
Vallianou, I.
Sagiadinou, E.
Tsokanas, D.
Theodorelou, R.
Papadopoulou, A.
Triantafyllou, E.
Sakellari, I.
Costeas, P.
Chatzidimitriou, A.
Yannaki, E.
Spyridonidis, A.
CYTOTHERAPY, 2024, 26 (06) : S12 - S12
[6] First-in-human phase I trial of DC immunotherapy for early RA
Jenny Buckland
Nature Reviews Rheumatology, 2015, 11 (8) : 443 - 443
[7] First-in-human clinical trial of genetically engineered B cells: Application to the treatment of mucopolysaccharidosis type I
McIvor, R. Scott
Hampe, Christiane S.
Grandea, Glen
Olson, Erik R.
Meeker, Kole D.
Papia, Cassidy
Solan, Joell
Hayes, Robert
Ainsworth, Sean
Orchard, Paul J.
Wesley, Jacob
Sikorski, Robert
MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
[8] First-in-human phase I trial of a novel epothilone, KOS-1584.
Villalona-Calero, M.
Goel, S.
Schaaf, L.
McCracken, B.
Desai, K.
Cropp, G.
Zhou, Y.
Johnson, R. G.
Hannah, A. L.
Mani, S.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 79S - 79S
[9] A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles for potent cancer immunotherapy in patients with malignant melanoma
Jabulowsky, Robert A.
Loquai, Carmen
Diken, Mustafa
Kranz, Lena M.
Haas, Heinrich
Attig, Sebastian
Bidmon, Nicole
Buck, Janina
Derhovanessian, Evelyne
Diekmann, Jan
Fritz, Daniel
Jahndel, Veronika
Kemmer-Brueck, Alexandra
Kuehlcke, Klaus
Kuhn, Andreas N.
Langguth, Peter
Luxemburger, Ulrich
Meng, Martin
Mueller, Felicitas
Rae, Richard
Sari, Fatih
Schwarck-Kokarakis, Doreen
Seck, Christine
Spiess, Kristina
Witt, Meike
Hassel, Jessica C.
Utikal, Jochen
Kaufmann, Roland
Kreiter, Sebastian
Huber, Christoph
Tuereci, Oezlem
Sahin, Ugur
CANCER RESEARCH, 2016, 76
[10] Evaluation of NTP42, a novel thromboxane receptor antagonist, in a first-in-human phase I clinical trial
Reid, Helen M.
Maginn, Mark
Perkins, C. Michael
Mulvaney, Eamon P.
Boyce, Malcolm
Yamamoto, Takahiro
Kinsella, B. Therese
FRONTIERS IN PHARMACOLOGY, 2023, 14

← 1 2 3 4 5 →